Search

Alkermes PLC

Gesloten

SectorGezondheidszorg

48.84 1.1

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

47.47

Max

49

Belangrijke statistieken

By Trading Economics

Inkomsten

67M

501K

Verkoop

103M

496M

K/W

Sectorgemiddelde

131.184

57.371

EPS

0.52

Winstmarge

0.101

Werknemers

2,050

EBITDA

76M

54M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+20.53% upside

Dividenden

By Acuity

Volgende Winsten

27 okt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-426M

8.4B

Vorige openingsprijs

47.74

Vorige sluitingsprijs

48.84

Nieuwssentiment

By Acuity

10%

90%

8 / 340 Rangschikking in Healthcare

Alkermes PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 aug 2026, 19:51 UTC

Alkermes Plc's shares are higher, supported by strong biotechnology sector momentum, though the stock is pulling back from earlier session highs.

20 aug 2026, 20:01 UTC

Alkermes Plc shares are lower, impacted by broader weakness in the Biotechnology sector. The stock is trading below its 20-day moving average.

19 aug 2026, 19:26 UTC

Alkermes Plc is trading higher, maintaining momentum since Tuesday's close, despite no specific news driving the price movement.

18 aug 2026, 19:16 UTC

News

Alkermes Plc shares are lower after an insider sold 7,576 shares at prices between $49.19 and $49.65, raising investor concerns about the outlook.

17 aug 2026, 23:31 UTC

Alkermes Plc shares are higher in after-market trading, reflecting a cumulative gain since Monday's close amid broader market volatility and fluctuating crude oil prices.

14 aug 2026, 19:46 UTC

Alkermes Plc shares are lower today amid broader market weakness following a reported decline in U.S. retail sales for July.

13 aug 2026, 19:26 UTC

Alkermes Plc shares are lower during Thursday's session, breaking a trend of higher closes. Broader market sentiment may be influenced by rising jobless claims.

12 aug 2026, 21:51 UTC

Alkermes shares are higher in after-market trading, reflecting positive momentum amid easing inflation concerns and a broader market recovery.

11 aug 2026, 19:26 UTC

Alkermes Plc shares are trading lower today, remaining near the lower end of their one-month range amid a lack of specific company news.

10 aug 2026, 19:46 UTC

Alkermes shares are advancing today, despite earlier fluctuations and no specific news. Broader market uncertainty follows a decline in U.S. employment reported last Friday.

6 aug 2026, 19:36 UTC

Alkermes Plc shares are lower today, reflecting unusual volatility and trading significantly below the 20-day moving average. No specific news was identified.

5 aug 2026, 19:56 UTC

Alkermes Plc shares are lower Wednesday, continuing a decline since Tuesday's close, despite broader market optimism from falling oil prices and potential diplomatic resolutions.

4 aug 2026, 19:26 UTC

News

Alkermes Plc shares are lower today amid concerns over recent insider sales by executives, despite the company's gross margin of 80.22%.

3 aug 2026, 20:02 UTC

Alkermes shares are higher today, driven by significant gains in the overall market and major technology stocks, despite earlier session pullbacks.

31 jul 2026, 19:36 UTC

Alkermes Plc shares are lower today, impacted by declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

30 jul 2026, 19:58 UTC

Alkermes Plc shares are higher during Thursday's session, reflecting a broader recovery in tech shares despite remaining below the 20-day moving average.

29 jul 2026, 20:03 UTC

News
Macro Event

Shares declining despite price target increases from JP Morgan, Baird.

28 jul 2026, 20:02 UTC

News
Event

Alkermes Plc shares are lower after reporting second-quarter earnings of 0 cents per share, below the consensus estimate of 29 cents.

24 jul 2026, 19:46 UTC

Alkermes Plc shares are lower today, pulling back after an early high. No specific news has been identified to explain the decline.

22 jul 2026, 19:36 UTC

Alkermes Plc shares are lower today, despite an earlier session high, amid rising crude oil prices and concerns over potential supply disruptions.

21 jul 2026, 18:46 UTC

Alkermes shares are higher today, supported by improved market sentiment and renewed interest in AI stocks. The asset is trading near its one-month range high.

20 jul 2026, 22:01 UTC

Alkermes Plc shares declined after-market, retracing from earlier peaks. The asset is currently below its 20-day moving average.

Peer Vergelijking

Prijswijziging

Alkermes PLC Prognose

Koersdoel

By TipRanks

20.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 58.25 USD  20.53%

Hoogste 65 USD

Laagste 38 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Alkermes PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

12 ratings

9

Buy

2

Hold

1

Sell

Sentiment

By Acuity

8 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
help-icon Live chat